-
2
-
-
33845399128
-
The importance of patient-reported outcomes...Its all about patients
-
Bren L, (2006). The importance of patient-reported outcomes...Its all about patients. FDA Consum 40: 26-32.
-
(2006)
FDA Consum
, vol.40
, pp. 26-32
-
-
Bren, L.1
-
3
-
-
0016919875
-
Subjective measures of well-being
-
Campbell A, (1976). Subjective measures of well-being. Am Psychol 31: 117-124.
-
(1976)
Am Psychol
, vol.31
, pp. 117-124
-
-
Campbell, A.1
-
4
-
-
43949087240
-
Watch out, watch out, the FDA are about
-
Cano SJ, Hobart JC, (2008). Watch out, watch out, the FDA are about. Dev Med Child Neurol 50: 408-409.
-
(2008)
Dev Med Child Neurol
, vol.50
, pp. 408-409
-
-
Cano, S.J.1
Hobart, J.C.2
-
5
-
-
0033544430
-
Total neuropathy score: Validation and reliability study
-
Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T, (1999). Total neuropathy score: validation and reliability study. Neurology 53: 1660-1664.
-
(1999)
Neurology
, vol.53
, pp. 1660-1664
-
-
Cornblath, D.R.1
Chaudhry, V.2
Carter, K.3
Lee, D.4
Seysedadr, M.5
Miernicki, M.6
Joh, T.7
-
6
-
-
36148981831
-
Rating scales as outcome measures for clinical trials in neurology: Problems, solutions, and recommendations
-
Hobart JC, Cano SJ, Zajicek JP, Thompson AJ, (2007). Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 6: 1094-1105.
-
(2007)
Lancet Neurol
, vol.6
, pp. 1094-1105
-
-
Hobart, J.C.1
Cano, S.J.2
Zajicek, J.P.3
Thompson, A.J.4
-
7
-
-
84882375832
-
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: Results of a randomized, double-masked, controlled trial
-
Lewis RA, McDermott MP, Herrmann DN, Hoke A, Clawson LL, Siskind C, Feely SM, Miller LJ, Barohn RJ, Smith P, Luebbe E, Wu X, Shy ME, (2013). High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 70: 981-987.
-
(2013)
JAMA Neurol
, vol.70
, pp. 981-987
-
-
Lewis, R.A.1
McDermott, M.P.2
Herrmann, D.N.3
Hoke, A.4
Clawson, L.L.5
Siskind, C.6
Feely, S.M.7
Miller, L.J.8
Barohn, R.J.9
Smith, P.10
Luebbe, E.11
Wu, X.12
Shy, M.E.13
-
8
-
-
80055011529
-
Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease
-
Murphy SM, Herrmann DN, McDermott MP, Scherer SS, Shy ME, Reilly MM, Pareyson D, (2011). Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 16: 191-198.
-
(2011)
J Peripher Nerv Syst
, vol.16
, pp. 191-198
-
-
Murphy, S.M.1
Herrmann, D.N.2
McDermott, M.P.3
Scherer, S.S.4
Shy, M.E.5
Reilly, M.M.6
Pareyson, D.7
-
9
-
-
79952736703
-
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): A double-blind randomised trial
-
CMT-TRIAAL; CMT-TRAUK groups.
-
Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laura M, Radice D, Calabrese D, Hughes RA, Solari A,; CMT-TRIAAL; CMT-TRAUK groups (2011). Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 10: 320-328.
-
(2011)
Lancet Neurol
, vol.10
, pp. 320-328
-
-
Pareyson, D.1
Reilly, M.M.2
Schenone, A.3
Fabrizi, G.M.4
Cavallaro, T.5
Santoro, L.6
Vita, G.7
Quattrone, A.8
Padua, L.9
Gemignani, F.10
Visioli, F.11
Laura, M.12
Radice, D.13
Calabrese, D.14
Hughes, R.A.15
Solari, A.16
-
11
-
-
78650170260
-
168th ENMC International Workshop: Outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT)
-
Reilly MM, Shy ME, Muntoni F, Pareyson D, (2010). 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord 20: 839-846.
-
(2010)
Neuromuscul Disord
, vol.20
, pp. 839-846
-
-
Reilly, M.M.1
Shy, M.E.2
Muntoni, F.3
Pareyson, D.4
-
12
-
-
16844381836
-
Reliability and validity of the CMT neuropathy score as a measure of disability
-
Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, Li J, Lewis RA, Reilly M, (2005). Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64: 1209-1214.
-
(2005)
Neurology
, vol.64
, pp. 1209-1214
-
-
Shy, M.E.1
Blake, J.2
Krajewski, K.3
Fuerst, D.R.4
Laura, M.5
Hahn, A.F.6
Li, J.7
Lewis, R.A.8
Reilly, M.9
-
13
-
-
34047241725
-
CMT1X phenotypes represent loss of GJB1 gene function
-
Shy ME, Siskind C, Swan ER, Krajewski KM, Doherty T, Fuerst DR, Ainsworth PJ, Lewis RA, Scherer SS, Hahn AF, (2007). CMT1X phenotypes represent loss of GJB1 gene function. Neurology 68: 849-855.
-
(2007)
Neurology
, vol.68
, pp. 849-855
-
-
Shy, M.E.1
Siskind, C.2
Swan, E.R.3
Krajewski, K.M.4
Doherty, T.5
Fuerst, D.R.6
Ainsworth, P.J.7
Lewis, R.A.8
Scherer, S.S.9
Hahn, A.F.10
-
14
-
-
39749139561
-
Neuropathy progression in Charcot-Marie-Tooth disease type 1A
-
Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, Herrmann D, Lewis RA, McDermott MP, (2008). Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 70: 378-383.
-
(2008)
Neurology
, vol.70
, pp. 378-383
-
-
Shy, M.E.1
Chen, L.2
Swan, E.R.3
Taube, R.4
Krajewski, K.M.5
Herrmann, D.6
Lewis, R.A.7
McDermott, M.P.8
-
15
-
-
0016266593
-
Genetic and clinical aspects of Charcot-Marie-Tooth's disease
-
Skre H, (1974). Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 6: 98-118.
-
(1974)
Clin Genet
, vol.6
, pp. 98-118
-
-
Skre, H.1
|